Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ginkgo Bioworks Inc. is currently navigating 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 3 distinct art units. This distribution shows that each pending matter is being handled by a unique examiner in a unique art unit, spreading the portfolio across multiple points of contact. Such a spread suggests that the company's current filings cover a variety of technical sub-niches within the broader biotechnology field, as each matter has triggered review by a different specialized group.
JOHNSON, ALLISON MARIE is the busiest examiner for the portfolio, with 1 pending office action under their review. This single action constitutes a portion of the 3 pending office actions currently active for the company. The presence of multiple distinct art units and examiners indicates a lack of examiner concentration, which may require the company to manage separate prosecution tracks simultaneously. Each pending office action represents a distinct opportunity for patent allowance, but also requires individual attention to the specific preferences of the 1 examiner involved in each case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
| VANNI, GEORGE STEVEN | 1 | 66.8% | +25.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283688 | ORGANOPHOSPHORUS NERVE AGENT HYDROLYZING ENZYMES | JOHNSON, ALLISON MARIE | — |
| 17959679 | HIGH-THROUGHPUT AUTOMATED STRAIN LIBRARY GENERATOR | HUMPHRIES, NICHOLAS ADAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283688 | ORGANOPHOSPHORUS NERVE AGENT HYDROLYZING ENZYMES | JOHNSON, ALLISON MARIE | — |
| 17959679 | HIGH-THROUGHPUT AUTOMATED STRAIN LIBRARY GENERATOR | HUMPHRIES, NICHOLAS ADAM | — |
| 17320513 | METHODS FOR MAKING A SYNTHETIC GENE | VANNI, GEORGE STEVEN | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1631 | 1 |
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18283688 | ORGANOPHOSPHORUS NERVE AGENT HYDROLYZING ENZYMES | JOHNSON, ALLISON MARIE | 1638 | §102§103§112 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 17959679 | HIGH-THROUGHPUT AUTOMATED STRAIN LIBRARY GENERATOR | HUMPHRIES, NICHOLAS ADAM | 1631 | §102§112 | Non-Final OA | — | Pending | Oct 04, 2022 |
| 17320513 | METHODS FOR MAKING A SYNTHETIC GENE | VANNI, GEORGE STEVEN | 1686 | §112DP | Non-Final OA | — | Pending | May 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGinkgo Bioworks Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Allison Marie Johnson has the most, with 1 of Ginkgo Bioworks Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
